InSilico Medicine (3696) Selected for Inclusion in Hang Seng Composite Index

Bulletin Express

Feb 20

InSilico Medicine Cayman TopCo (“Insilico Medicine” or “the Company”) has been chosen by Hang Seng Indexes Company Limited to become a constituent stock of the Hang Seng Composite Index (“HSCI”), effective March 9, 2026. According to the announcement, the Company’s shares are expected to meet the inclusion criteria for trading via both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect upon this addition.

The Company’s board of directors stated that inclusion in the HSCI highlights recognition from the international capital market regarding Insilico Medicine’s industry position and business value. The board further noted that this development could improve stock liquidity, diversify its shareholder base, and support the Company’s long-term development.

Insilico Medicine is a global biotechnology enterprise that leverages artificial intelligence and automation technologies to enhance drug discovery and drive progress within the life sciences. It was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK, focusing on areas such as fibrosis, oncology, immunology, pain, and metabolic disorders, alongside broader applications of its Pharma.AI platform.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1158327840"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158327840\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158327840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 08:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158327840","market":"us","top_or_hot":-1,"title":"InSilico Medicine (3696) Selected for Inclusion in Hang Seng Composite Index","media":"Bulletin Express","content":"<p>InSilico Medicine Cayman TopCo (“Insilico Medicine” or “the Company”) has been chosen by Hang Seng Indexes Company Limited to become a constituent stock of the Hang Seng Composite Index (“HSCI”), effective March 9, 2026. According to the announcement, the Company’s shares are expected to meet the inclusion criteria for trading via both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect upon this addition.</p>\n<p>The Company’s board of directors stated that inclusion in the HSCI highlights recognition from the international capital market regarding Insilico Medicine’s industry position and business value. The board further noted that this development could improve stock liquidity, diversify its shareholder base, and support the Company’s long-term development.</p>\n<p>Insilico Medicine is a global biotechnology enterprise that leverages artificial intelligence and automation technologies to enhance drug discovery and drive progress within the life sciences. It was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK, focusing on areas such as fibrosis, oncology, immunology, pain, and metabolic disorders, alongside broader applications of its Pharma.AI platform.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InSilico Medicine (3696) Selected for Inclusion in Hang Seng Composite Index</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInSilico Medicine (3696) Selected for Inclusion in Hang Seng Composite Index\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-20 08:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>InSilico Medicine Cayman TopCo (“Insilico Medicine” or “the Company”) has been chosen by Hang Seng Indexes Company Limited to become a constituent stock of the Hang Seng Composite Index (“HSCI”), effective March 9, 2026. According to the announcement, the Company’s shares are expected to meet the inclusion criteria for trading via both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect upon this addition.</p>\n<p>The Company’s board of directors stated that inclusion in the HSCI highlights recognition from the international capital market regarding Insilico Medicine’s industry position and business value. The board further noted that this development could improve stock liquidity, diversify its shareholder base, and support the Company’s long-term development.</p>\n<p>Insilico Medicine is a global biotechnology enterprise that leverages artificial intelligence and automation technologies to enhance drug discovery and drive progress within the life sciences. It was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK, focusing on areas such as fibrosis, oncology, immunology, pain, and metabolic disorders, alongside broader applications of its Pharma.AI platform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1158327840","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158327840","pubTimestamp":1771547059,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"InSilico Medicine Cayman TopCo (“Insilico Medicine” or “the Company”) has been chosen by Hang Seng Indexes Company Limited to become a constituent stock of the Hang Seng Composite Index (“HSCI”),...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"英矽智能(3696)获选纳入恒生综合指数","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"InSilico Medicine Cayman TopCo (“Insilico Medicine” or “the Company”) has been chosen by Hang Seng Indexes Company Limited to become a constituent stock of the Hang Seng Composite Index (“HSCI”), effective March 9, 2026. According to the announcement, the Company’s shares are expected to meet the inclusion criteria for trading via both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect upon this addition.\nThe Company’s board of directors stated that inclusion in the HSCI highlights recognition from the international capital market regarding Insilico Medicine’s industry position and business value. The board further noted that this development could improve stock liquidity, diversify its shareholder base, and support the Company’s long-term development.\nInsilico Medicine is a global biotechnology enterprise that leverages artificial intelligence and automation technologies to enhance drug discovery and drive progress within the life sciences. It was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK, focusing on areas such as fibrosis, oncology, immunology, pain, and metabolic disorders, alongside broader applications of its Pharma.AI platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}